Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTAC-0001 in Recurrent Glioblastoma Progressed on Bevacizumab
NCT03856099Phase 2Terminated
- Sponsor
- PharmAbcine
- Start
- Nov 2019
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of olinvacimab in glioblastoma (GBM), sponsored by PharmAbcine. Started Nov 2019; status: terminated.
02
Drugs
olinvacimab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03856099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03856099.